Prediction of recurrence following hepatectomy in patients with hepatitis C virus infection‐related hepatocellular carcinoma who achieved a sustained virological response. Issue 11 (24th April 2017)

• Record Type: Journal Article
• Authors: Okimoto, Sho; Kobayashi, Tsuyoshi; Kuroda, Shintaro; Ishiyama, Kohei; Ide, Kentaro; Ohira, Masahiro; Tahara, Hiroyuki; Shimizu, Seiichi; Iwako, Hiroshi; Hamaoka, Michinori; Honmyo, Naruhiko; Yamaguchi, Megumi; Ohdan, Hideki
• Is Part Of: Hepatology research. Volume 47:Issue 11(2017)
• Page Start: 1186
• Page End: 1195
• Publication Date: 2017-04-24
• Subjects: antiviral agent -- hepatectomy -- hepatitis C virus -- hepatocellular carcinoma -- recurrence -- survival; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12896
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract : Aim: The risk of hepatitis C virus infection‐ related hepatocellular carcinoma (HCC) is lower, with a better prognosis, in patients who achieve a sustained virological response (SVR) than in those who do not. We aimed to identify risk factors of post‐hepatectomy HCC recurrence in patients who achieved a SVR. Methods: This retrospective study included 349 HCC patients who underwent an initial radical hepatectomy at our institution between January 2005 and December 2014. Sixty‐eight patients had achieved a SVR (the SVR group) and 281 patients had not (the non‐SVR group). Clinical characteristics and long‐term outcomes were compared between the two groups. Univariate and multivariate analyses identified variables associated with recurrence‐free survival in the SVR group. Results: Post‐hepatectomy overall and recurrence‐free survival rates were significantly higher in the SVR group than the non‐SVR group ( P < 0.01 and <0.05, respectively). Univariate analysis of post‐hepatectomy recurrence‐free survival in the SVR group revealed multiple significant factors: aspartate aminotransferase, 25 IU/L or more ( P = 0.01); indocyanine green retention rate at 15 min, 20.0% or less ( P < 0.05); hepatic vascular invasion ( P < 0.05); and an interval of months or less between achieving a SVR and hepatectomy ( P < 0.01). Multivariate analysis confirmed an interval of 30 months or less between achieving a SVR and hepatectomy as an independent prognostic factor of recurrence‐free survival (hazard ratio, 2.30; 95.0% confidence interval, 1.04–5.13; P < 0.05). Conclusion: The interval between achieving a SVR and hepatectomy is an important predictor of recurrence in hepatitis C virus infection‐related HCC patients who achieved a SVR.